Global Markets for Hyaluronic Acid Viscosupplementation

Published by: Millennium Research Group

Published: Dec. 31, 2010


Table of Contents


EXECUTIVE SUMMARY

METHODOLOGY

1.0 HYALURONIC ACID VISCOSUPPLEMENTATION BACKGROUND

1.1 Osteoarthritis Incidence

1.2 Treatment Alternatives

1.2.1 Nonpharmacologic Treatments

1.2.2 Nonsteroidal Anti-Inflammatory Drugs

1.2.3 Cyclooxygenase-2 Inhibitors

1.2.4 Hyaluronic Acid Viscosupplementation

2.0 GLOBAL HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

2.1 Market Overview

2.2 Market Analysis

2.2.1 Key Report Updates

2.2.2 Procedures

2.2.3 Market Forecast

2.2.3.1 US Hyaluronic Acid Viscosupplementation Market

2.2.3.2 European Hyaluronic Acid Viscosupplementation Market

2.2.3.3 Japanese Hyaluronic Acid Viscosupplementation Market

2.2.3.4 Brazilian, Indian, and Chinese Hyaluronic Acid Viscosupplementation Market

2.3 Competitive Analysis

2.3.1 Competitive Landscape

2.3.2 Market Shares

3.0 US HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

3.1 Market Overview

3.2 Market Analysis

3.2.1 Procedures

3.2.2 Hyaluronic Acid Viscosupplementation Treatments by Segment (1-Injection, 3-Injection, and 5- Injection)

3.2.3 Hyaluronic Acid Viscosupplementation Treatments by Application (Knee, Shoulder, Hip, and Other)

3.2.4 Hyaluronic Acid Viscosupplementation Treatments by Site (Sports Medicine Clinic, Rheumatology Clinic, Primary Care Clinic, and Other)

3.2.5 Market Forecast

3.2.6 Market Drivers and Limiters

3.2.6.1 Market Drivers

3.2.6.2 Market Limiters

3.3 Competitive Analysis

3.3.1 Market Shares

3.3.2 Competitor Discussions (in Alphabetical Order)

3.3.2.1 Leading Competitors

Anika Therapeutics (through distibutor DePuy Mitek)

Ferring Pharmaceuticals

Fidia Farmaceutici (through distributor sanofi-aventis)

Genzyme Biosurgery

Seikagaku (through distributor Smith & Nephew)

3.3.2.2 Emerging Competitors and Technologies

Carbylan BioSurgery’s ActaVisc and ActaVisc Mx

Orthogen’s Orthokine

Regenerative Sciences’ Regenexx

Seikagaku’s Gel-200

4.0 EUROPEAN HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

4.1 Market Overview

4.2 Market Analysis

4.2.1 Procedures

4.2.1.1 French Hyaluronic Acid Viscosupplementation Procedures

4.2.1.2 German Hyaluronic Acid Viscosupplementation Procedures

4.2.1.3 Italian Hyaluronic Acid Viscosupplementation Procedures

4.2.1.4 Spanish Hyaluronic Acid Viscosupplementation Procedures

4.2.1.5 UK Hyaluronic Acid Viscosupplementation Procedures

4.2.2 Market Forecast

4.2.2.1 French Hyaluronic Acid Viscosupplementation Market

4.2.2.2 German Hyaluronic Acid Viscosupplementation Market

4.2.2.3 Italian Hyaluronic Acid Viscosupplementation Market

4.2.2.4 Spanish Hyaluronic Acid Viscosupplementation Market

4.2.2.5 UK Hyaluronic Acid Viscosupplementation Market

4.2.3 Market Drivers and Limiters

4.2.3.1 Market Drivers

4.2.3.2 Market Limiters

4.3 Competitive Analysis

4.3.1 Competitive Landscape

4.3.2 Market Shares

4.3.3 Competitor Discussions (in Alphabetical Order)

Anika Therapeutics

Bioniche Pharma

Croma Pharma

Fidia Farmaceutici

Genzyme Biosurgery

Laboratoires Genévrier

Merckle Recordati

Q-Med

Rottapharm

Tedec-Meiji Farma

TRB Chemedica

Other

5.0 JAPANESE HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

5.1 Market Overview

5.2 Market Analysis

5.2.1 Procedures

5.2.2 Hyaluronic Acid Viscosupplementation Treatments By Segment (1-Injection, 3-Injection, and 5- Injection)

5.2.3 Hyaluronic Acid Viscosupplementation Treatments By Application (Knee, Shoulder, Hip, and Other)

5.2.4 Hyaluronic Acid Viscosupplementation Treatments By Product Type (Brand Name and Generic)

5.2.5 Market Forecast

5.2.6 Market Drivers and Limiters

5.2.6.1 Market Drivers

5.2.6.2 Market Limiters

5.3 Competitive Analysis

5.3.1 Competitive Landscape

5.3.2 Market Shares

5.3.3 Competitor Discussions (in Alphabetical Order)

5.3.3.1 Leading Competitors

Chugai Pharmaceutical

Maruho

Seikagaku

Other

5.3.3.2 Emerging Competitors

Genzyme Biosurgery

6.0 BRAZILIAN, INDIAN, AND CHINESE HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

6.1 Market Overview

6.2 Market Analysis

6.2.1 Procedures

6.2.1.1 Brazilian Hyaluronic Acid Viscosupplementation Treatments

6.2.1.2 Indian Hyaluronic Acid Viscosupplementation Treatments

6.2.1.3 Chinese Hyaluronic Acid Viscosupplementation Treatments

6.2.2 Market Forecast

6.2.2.1 Brazilian Hyaluronic Acid Viscosupplementation Market

6.2.2.2 Indian Hyaluronic Acid Viscosupplementation Market

6.2.2.3 Chinese Hyaluronic Acid Viscosupplementation Market

6.2.3 Market Drivers and Limiters

6.2.3.1 Market Drivers

6.2.3.2 Market Limiters

6.3 Competitive Analysis

6.3.1 Competitive Landscape

6.3.2 Market Shares

6.3.3 Competitor Discussions (in Alphabetical Order)

Genzyme Biosurgery

Fidia Farmaceutici

Seikagaku

Shandong Bausch & Lomb Freda Pharmaceutical

Shanghai BAIJIAYI Pharmaceutical

Other

APPENDIX A: MRG ACRONYMS AND INITIALISMS

APPENDIX B: OSTEOARTHRITIS EPIDEMIOLOGY

APPENDIX C: SUPPLEMENTAL FIGURES

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

Figure 1: HA Viscosupplementation Market, by Region, Global (US$), 2009-2015

Figure 2: HA Viscosupplementation Treatments, by Segment, as a % of Total, US, 2009-2015

Figure 3: HA Viscosupplementation Market, by Segment, as a % of Total, Europe, 2010 and 2015

Figure 4: HA Viscosupplementation Market, by Segment, Japan (US$), 2009-2015

Figure 5: HA Viscosupplementation Market, by Country, BIC (US$), 2009-2015

Table 1: Companies Mentioned in This Report

METHODOLOGY

Table 2: Average Currency Exchange Rates, 2010

1.0 HYALURONIC ACID VISCOSUPPLEMENTATION BACKGROUND

Table 3: Select HA Viscosupplementation Companies and Products, US, 2010

Table 4: Select HA Viscosupplementation Companies and Products, Japan, 2010

2.0 GLOBAL HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

Figure 6: HA Viscosupplementation Market, Global (US$), 2009-2015

Table 5: Key Report Updates, 2011

Table 6: HA Viscosupplementation Treatments, by Region, Global, 2009-2015

Table 7: HA Viscosupplementation Treatments, by Segment, Global, 2009-2015

Table 8: HA Viscosupplementation Treatments, by Application, Global, 2009-2015

Table 9: HA Viscosupplementation Market, by Region, Global (US$), 2009-2015

Table 10: Leading Competitors in the HA Viscosupplementation Market, by Region, as a % of Total, Global, 2010

3.0 US HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

Figure 7: HA Viscosupplementation Treatments, by Segment, as a % of Total, US, 2010 and 2015

Table 11: HA Viscosupplementation Treatments and Injections, US, 2009-2015

Table 12: HA Viscosupplementation Treatments, by Segment, US, 2009-2015

Table 13: HA Viscosupplementation Treatments and Injections, by Application, US, 2009-2015

Table 14: HA Viscosupplementation Treatment and Injection Growth, by Application, US, 2010-2015

Table 15: HA Viscosupplementation Treatments and Injections, by Application, as a % of Total, US, 2009-2015

Table 16: HA Viscosupplementation Procedures, by Site, US, 2009-2015

Table 17: HA Viscosupplementation Market, US (US$), 2009-2015

Table 18: Drivers and Limiters of the HA Viscosupplementation Market, US

Table 19: Leading Competitors in the HA Viscosupplementation Market, as a % of Total, US, 2009 and 2010

4.0 EUROPEAN HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

Figure 8: HA Viscosupplementation Market, by Segment, Europe (US$), 2009-2015

Table 20: HA Viscosupplementation Treatments and Injections, by Segment, Europe, 2009-2015

Table 21: HA Viscosupplementation Treatments, by Application, Europe, 2009-2015

Table 22: HA Viscosupplementation Treatments and Injections, by Segment, France, 2009-2015

Table 23: HA Viscosupplementation Treatments, by Application, France, 2009-2015

Table 24: HA Viscosupplementation Treatments and Injections, by Segment, Germany, 2009-2015

Table 25: HA Viscosupplementation Treatments, by Application, Germany, 2009-2015

Table 26: HA Viscosupplementation Treatments and Injections, by Segment, Italy, 2009-2015

Table 27: HA Viscosupplementation Treatments, by Application, Europe, Italy, 2009-2015

Table 28: HA Viscosupplementation Treatments and Injections, by Segment, Spain, 2009-2015

Table 29: HA Viscosupplementation Treatments, by Application, Spain, 2009-2015

Table 30: HA Viscosupplementation Treatments and Injections, by Segment, UK, 2009-2015

Table 31: HA Viscosupplementation Treatments, by Application, UK, 2009-2015

Table 32: HA Viscosupplementation Market, by Segment, Europe (US$), 2009-2015

Table 33: HA Viscosupplementation Market, by Segment, Europe (€), 2009-2015

Table 34: HA Viscosupplementation Market Growth, by Segment, Europe, 2010-2015

Table 35: HA Viscosupplementation Market, by Segment, as a % of Total, Europe, 2009-2015

Table 36: HA Viscosupplementation Market, by Segment, France (US$), 2009-2015

Table 37: HA Viscosupplementation Market, by Segment, France (€), 2009-2015

Table 38: HA Viscosupplementation Market Growth, by Segment, France, 2010-2015

Table 39: HA Viscosupplementation Market, by Segment, as a % of Total, France, 2009-2015

Table 40: HA Viscosupplementation Market, by Segment, Germany, (US$), 2009-2015

Table 41: HA Viscosupplementation Market, by Segment, Germany, (€), 2009-2015

Table 42: HA Viscosupplementation Market Growth, by Segment, Germany, 2010-2015

Table 43: HA Viscosupplementation Market, by Segment, as a % of Total, Germany, 2009-2015

Table 44: HA Viscosupplementation Market, by Segment, Italy (US$), 2009-2015

Table 45: HA Viscosupplementation Market, by Segment, Italy (€), 2009-2015

Table 46: HA Viscosupplementation Market Growth, by Segment, Italy, 2010-2015

Table 47: HA Viscosupplementation Market, by Segment, as a % of Total, Italy, 2009-2015

Table 48: HA Viscosupplementation Market, by Segment, Spain (US$), 2009-2015

Table 49: HA Viscosupplementation Market, by Segment, Spain (€), 2009-2015

Table 50: HA Viscosupplementation Market Growth, by Segment, Spain, 2010-2015

Table 51: HA Viscosupplementation Market, by Segment, as a % of Total, Spain, 2009-2015

Table 52: HA Viscosupplementation Market, by Segment, UK (US$), 2009-2015

Table 53: HA Viscosupplementation Market, by Segment, UK (€), 2009-2015

Table 54: HA Viscosupplementation Market, by Segment, UK (£), 2009-2015

Table 55: HA Viscosupplementation Market Growth, by Segment, UK, 2010-2015

Table 56: HA Viscosupplementation Market, by Segment, as a % of Total, UK, 2009-2015

Table 57: Drivers and Limiters of the HA Viscosupplementation Market, Europe

Table 58: Leading Competitors in the HA Viscosupplementation Market, by Country, as a % of Total, Europe, 2010

5.0 JAPANESE HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

Figure 9: HA Viscosupplementation Market, Japan (US$), 2009-2015

Table 59: HA Viscosupplementation Treatments and Injections, by Segment, Japan, 2009-2015

Table 60: HA Viscosupplementation Treatments, by Application, Japan, 2009-2015

Table 61: HA Viscosupplementation Treatments, by Type, Japan, 2009-2015

Table 62: HA Viscosupplementation Market, by Segment, Japan (US$), 2009-2015

Table 63: HA Viscosupplementation Market, by Segment, Japan (¥), 2009-2015

Table 64: HA Viscosupplementation Market Growth, by Segment, Japan, 2010-2015

Table 65: HA Viscosupplementation Market, by Segment, as a % of Total, Japan, 2009-2015

Table 66: HA Viscosupplementation Market, by Type, Japan (US$), 2009-2015

Table 67: HA Viscosupplementation Market, by Type, Japan (¥), 2009-2015

Table 68: HA Viscosupplementation Market Growth, by Type, Japan, 2010-2015

Table 69: HA Viscosupplementation Market, by Type, as a % of Total, Japan, 2009-2015

Table 70: Drivers and Limiters of the HA Viscosupplementation Market, Japan

Table 71: Leading Competitors in the HA Viscosupplementation Market, as a % of Total, Japan, 2010

6.0 BRAZILIAN, INDIAN, AND CHINESE HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

Figure 10: HA Viscosupplementation Market, BIC (US$), 2009-2015

Table 72: HA Viscosupplementation Treatments, by Country, BIC, 2009-2015

Table 73: HA Viscosupplementation Treatments and Injections, by Segment, BIC, 2009-2015

Table 74: HA Viscosupplementation Treatments, by Application, BIC, 2009-2015

Table 75: HA Viscosupplementation Treatments and Injections, by Segment, Brazil, 2009-2015

Table 76: HA Viscosupplementation Treatments, by Application, Brazil, 2009-2015

Table 77: HA Viscosupplementation Treatments and Injections, by Segment, India, 2009-2015

Table 78: HA Viscosupplementation Treatments, by Application, India, 2009-2015

Table 79: HA Viscosupplementation Treatments and Injections, by Segment, China, 2009-2015

Table 80: HA Viscosupplementation Treatments, by Application, China, 2009-2015

Table 81: HA Viscosupplementation Market, by Country, BIC (US$), 2009-2015

Table 82: HA Viscosupplementation Market, by Segment, BIC (US$), 2009-2015

Table 83: HA Viscosupplementation Market Growth, by Segment, BIC, 2010-2015

Table 84: HA Viscosupplementation Market, by Segment, as a % of Total, BIC, 2009-2015

Table 85: HA Viscosupplementation Market, by Segment, Brazil (US$), 2009-2015

Table 86: HA Viscosupplementation Market, by Segment, Brazil (R$), 2009-2015

Table 87: HA Viscosupplementation Market Growth, by Segment, Brazil, 2010-2015

Table 88: HA Viscosupplementation Market, by Segment, as a % of Total, Brazil, 2009-2015

Table 89: HA Viscosupplementation Market, by Segment, India (US$), 2009-2015

Table 90: HA Viscosupplementation Market, by Segment, India (INR), 2009-2015

Table 91: HA Viscosupplementation Market Growth, by Segment, India, 2010-2015

Table 92: HA Viscosupplementation Market, by Segment, as a % of Total, India, 2009-2015

Table 93: HA Viscosupplementation Market, by Segment, China (US$), 2009-2015

Table 94: HA Viscosupplementation Market, by Segment, China (CNY), 2009-2015

Table 95: HA Viscosupplementation Market Growth, by Segment, China, 2010-2015

Table 96: HA Viscosupplementation Market, by Segment, as a % of Total, China, 2009-2015

Table 97: Drivers and Limiters of the HA Viscosupplementation Market, BIC

Table 98: Leading Competitors in the HA Viscosupplementation Market, as a % of Total, BIC, 2010

APPENDIX A: MRG ACRONYMS AND INITIALISMS

MRG Acronyms and Initialisms

APPENDIX B: OSTEOARTHRITIS EPIDEMIOLOGY

Table 99: Prevalence of Osteoarthritis, by Age, Global, 2009-2015

Table 100: Prevalence of Osteoarthritis, by Age, US, 2009-2015

Table 101: Prevalence of Osteoarthritis, by Age, France, 2010-2015

Table 102: Prevalence of Osteoarthritis, by Age, Germany, 2010-2015

Table 103: Prevalence of Osteoarthritis, by Age, Italy, 2010-2015

Table 104: Prevalence of Osteoarthritis, by Age, Spain, 2010-2015

Table 105: Prevalence of Osteoarthritis, by Age, UK, 2010-2015

Table 106: Prevalence of Osteoarthritis, by Age, Japan, 2009-2015

APPENDIX C: SUPPLEMENTAL FIGURES

Figure 11: HA Viscosupplementation Market, by Region, Global (US$), 2009-2015 (Detailed Format)

Figure 12: HA Viscosupplementation Treatments, by Segment, as a % of Total, US, 2009-2015 (Detailed Format)

Figure 13: HA Viscosupplementation Market, by Segment, as a % of Total, Europe, 2010 and 2015 (Detailed Format)

Figure 14: HA Viscosupplementation Market, by Segment, Japan (US$), 2009-2015 (Detailed Format)

Figure 15: HA Viscosupplementation Market, by Country, BIC (US$), 2009-2015 (Detailed Format)

Abstract

Introduction:

In 2010, the global market for hyaluronic acid (HA) viscosupplementation was valued at nearly $1.4 billion. The US maintained both the largest and fastest-growing market for HA viscosupplementation in 2010. Japan, the second-largest market globally, experienced a slight loss in market revenues in 2010 as a result of continuing biennial reimbursement cuts despite growth in treatment volumes that will continue steadily through 2015. The European market and emerging markets of Brazil, India, and China (BIC) together represent a significantly smaller portion of the global market; market revenue in both regions will grow, however, as a result of rising treatment volumes and the adoption of premium-priced products in many countries in these regions. Demand for HA viscosupplementation treatment volumes will also be fueled worldwide by the aging global population, which is more susceptible to osteoarthritis, the primary condition that requires HA viscosupplementation treatment. Moreover, rising obesity rates in most regions are also contributing to growing osteoarthritis prevalence rates, further raising demand for treatments. Increasing patient and physician awareness of the benefits of HA viscosupplementation compared to alternative treatments for osteoarthritis pain, such as nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors, is also helping to expand treatment volumes. While intense price competition and unfavorable reimbursement policies in many of the countries covered will limit average selling prices (ASPs), a trend toward shorter treatment regiments using premium-priced 3- and 1-injection products will contribute to overall increases in ASPs through 2015. Globally, the HA viscosupplementation market will experience strong growth over the forecast period.

Questions Answered in This Report:
  • In Europe, premium-priced 1- and 3-injection HA viscosupplementation products are becoming more popular because convenience has become a more important point of consideration compared to pricing for many patients. How will the adoption rate of 1-injection products differ across the various European countries? What are companies in the 3-injection and 5-injection segments doing to remain competitive? What is the outlook for the overall European HA viscosupplementation market over the course of the forecast period?
  • In the US, premium-priced 1-injection HA viscosupplementation products will be increasingly adopted over the forecast period. Will both 3- and 5-injection products be equally impacted? What is the expected impact of the introduction of other 1-injection products, such as Zimmer's Gel-200 and DePuy Mitek's MONOVISC? Will Smith & Nephew's Durolane enter the market before 2015?
  • In Japan, contrary to the previously expected trend, the percentage of treatments performed using brand name HA viscosupplementation products instead of generic competing products will slightly increase as a result of physician and patient preference for brands with strong established reputations. How are manufacturers of generic products responding to limited market share growth? How will the introduction of Genzyme's Synvisc 3-injection product (the first non-domestic and non–5-injection product available in Japan) affect the well-established and highly competitive Japanese market? What will the net effect on Japanese ASPs be from the shift in product mix? How will this impact the value of the Japanese HA viscosupplementation market?
  • In BIC, HA viscosupplementation is still a relatively new method of treatment; many physicians still look to administer alternative treatments, such as a combination of chondroitin and glucosamine in Brazil, ayurvedic practices in India, or traditional Chinese medicine in China. Nonetheless, following the introductions of well-recognized foreign brands within the past year with strong track records of safety and efficacy, physician awareness and confidence in HA viscosupplementation products will grow. Which country will show the strongest revenue growth moving into 2015 and why? How will the introduction and adoption of 1-injection products affect revenue growth across each HA viscosupplementation market? How will the lack of a 1-injection market in China affect its market size compared to Brazil and India?
Scope:

Regions covered: US, Europe (France, Germany, Italy, Spain, UK), Japan, Brazil, India, China

Procedure segmentation: Our analysis uses the following breakdown of procedures:
  • US
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
  • By site (sports medicine clinic, rheumatology clinic, primary care clinic, and other)
  • Europe
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, other)
  • Japan
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
  • By type (brand name and generic)
  • BIC
  • By segment (1-injection, 3-injection, and 5-injection)
  • By application (knee, shoulder, hip, and other)
Market segmentation: Our analysis uses the following breakdown of the market:
  • US
  • Europe
  • By segment (1-injection, 3-injection, and 5-injection)
  • Japan
  • By segment (1-injection, 3-injection, and 5-injection)
  • By type (brand name and generic)
  • BIC
  • By segment (1-injection, 3-injection, and 5-injection)
Market forecast features: Based on primary research with industry professionals, we use our proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, average selling prices, and market values over a 7-year period (2009–2015).

Competitive analysis: We provide a detailed analysis of the competitive landscape in the market, as well as market shares and qualitative discussions of the leading competitors in each market segment.

Get full details about this report >>
 
Learn more about this product


Price and delivery options
See related reports or call the number below for help from a research specialist.

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.